AMEX Extends Compliance Plan 07-13-05
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of
Report (Date of Earliest Event Reported): July
13, 2005
Commission
File No. 1-14778
DOR
BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its charter)
|
DELAWARE
|
|
41-1505029
|
|
(State
or other jurisdiction of incorporation or organization)
|
|
(I.R.S.
Employer Identification Number)
|
| |
|
|
|
1691
Michigan Ave., Suite 435
Miami,
FL
|
|
33139
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
| |
(305)
534-3383
|
|
| |
(Issuer’s
telephone number, including area code)
|
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item 3.01. Notice
of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Transfer of Listing.
On
July
13, 2005, the American Stock Exchange (“AMEX”) notified DOR BioPharma, Inc. (the
“Company”) that after review of the Company’s Compliance plan submitted on
December 30, 2004, and after review of the submission dated July 6, 2005, it
has
determined that, in accordance with Section 1009 of the Company Guide, the
period to regain compliance has been extended to October 15, 2005. This
extension is granted in order to regain compliance with the continued listing
standard of Section 1003 (a)(iii) of the Company Guide with shareholder’s equity
of less than $6,000,000 and losses from continuing operations and/or net losses
in its five most recent fiscal years.
The
Company must continue to provide the staff of AMEX with updates in conjunction
with the initiatives under the plan as appropriate or requested. The Company
will be subject to periodic review by the Exchange Staff during the extension
period. Failure to make progress consistent with the plan or to regain
compliance with the continued listing standards by the end of the extension
period could result in the Company being delisted from the American Stock
Exchange.
A
copy of
the press release announcing the notice is attached as Exhibit 99.1 to this
report.
Item
9.01. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit
No. Title
99.1
Press
release issued by DOR BioPharma, Inc. on July 13, 2005.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
DOR
BIOPHARMA,
INC.
By: /s/
Michael T. Sember
Name:
Michael T. Sember
Title:
President and Chief Executive Officer
Dated: July
13,
2005
Exhibit
Index
Exhibit
Number Description
of Exhibits
99.1
Press
Release of Registrant dated July 13, 2005